Atrial Fibrillation in Kidney Failure: Challenges in Risk Assessment and Anticoagulation Management

[1]  G. Breithardt,et al.  A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study , 2022, Circulation.

[2]  Kevin L. Thomas,et al.  Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial , 2022, Circulation.

[3]  S. Nopp,et al.  Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence , 2022, Frontiers in Cardiovascular Medicine.

[4]  N. Roetker,et al.  Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study. , 2022, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  W. Winkelmayer,et al.  Implantable Loop Recorder Monitoring and the Incidence of Previously Unrecognized Atrial Fibrillation in Patients on Hemodialysis , 2021, Kidney international reports.

[6]  W. Winkelmayer,et al.  Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. , 2021, Kidney international.

[7]  J. Carrero,et al.  Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function , 2021, European heart journal.

[8]  D. De Bacquer,et al.  Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial , 2021, Journal of the American Society of Nephrology : JASN.

[9]  G. Heine,et al.  Anticoagulation Management In Hemodialysis Patients With Atrial Fibrillation: Evidence And Opinion. , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  P. Kalra,et al.  Calciphylaxis in end-stage kidney disease: outcome data from the United Kingdom Calciphylaxis Study , 2021, Journal of Nephrology.

[11]  A. McGavigan,et al.  Atrial fibrillation burden: an update-the need for a CHA2DS2-VASc-AFBurden score. , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[12]  A. Levin,et al.  Anticoagulation for Patients with Atrial Fibrillation and End Stage Renal Disease on Dialysis: A National Survey. , 2020, The Canadian journal of cardiology.

[13]  F. Dekker,et al.  Bleeding risk of haemodialysis and peritoneal dialysis patients , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[15]  F. Pieruzzi,et al.  Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis , 2020, Journal of Nephrology.

[16]  G. Abela,et al.  Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease , 2020, JAMA network open.

[17]  Chava L. Ramspek,et al.  A systematic review and external validation of stroke prediction models demonstrates poor performance in dialysis patients. , 2020, Journal of clinical epidemiology.

[18]  S. Hohnloser,et al.  Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease , 2020, Circulation.

[19]  E. Peterson,et al.  Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. , 2020, American heart journal.

[20]  C. Hawley,et al.  The Australian Calciphylaxis Registry: reporting clinical features and outcomes of patients with calciphylaxis. , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  R. Passman,et al.  Stroke Risk as a Function of Atrial Fibrillation Duration and CHA2DS2-VASc Score. , 2019, Circulation.

[22]  A. Meinecke,et al.  Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. , 2019, The American journal of medicine.

[23]  M. Crowther,et al.  Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum , 2019, American journal of hematology.

[24]  M. Turakhia,et al.  Dialysis Modality and Incident Atrial Fibrillation in Older Patients With ESRD. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  A. Demchuk,et al.  Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors , 2019, The New England journal of medicine.

[26]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Journal of the American College of Cardiology.

[27]  P. Noseworthy,et al.  Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States , 2018, Circulation.

[28]  M. Chung,et al.  Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity A Scientific Statement From the American Heart Association , 2018, Circulation.

[29]  Rajiv Mahajan,et al.  Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis , 2018, European heart journal.

[30]  D. Charytan,et al.  Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle. , 2018, Kidney international.

[31]  B. Ritchie,et al.  Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study , 2018, Thrombosis and Haemostasis.

[32]  Wojciech Zareba,et al.  Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference , 2018, European heart journal.

[33]  J. Odeberg,et al.  Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. , 2017, Blood.

[34]  T. Mavrakanas,et al.  Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. , 2017, Journal of the American Society of Nephrology : JASN.

[35]  G. Rennert,et al.  Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. , 2017, Blood.

[36]  L. Friberg,et al.  Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction , 2017, Journal of the American Heart Association.

[37]  D. Bacquer,et al.  Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis. , 2017 .

[38]  M. Turakhia,et al.  Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease , 2016, Heart.

[39]  Prashanthan Sanders,et al.  The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. , 2016, European heart journal.

[40]  S. Kische,et al.  Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry , 2016, European heart journal.

[41]  Prashanthan Sanders,et al.  Temporal distribution of arrhythmic events in chronic kidney disease: Highest incidence in the long interdialytic period. , 2015, Heart rhythm.

[42]  D. De Bacquer,et al.  Dose-finding study of rivaroxaban in hemodialysis patients. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  M. Lebel,et al.  The impact of warfarin on the rate of progression of aortic stiffness in hemodialysis patients: a longitudinal study. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[44]  T. Chao,et al.  Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. , 2014, Heart rhythm.

[45]  Frank Beckers,et al.  Cryptogenic stroke and underlying atrial fibrillation. , 2014, The New England journal of medicine.

[46]  T. Wang,et al.  Relationships between Anticoagulation, Risk Scores and Adverse Outcomes in Dialysis Patients with Atrial Fibrillation. , 2014, Heart, lung & circulation.

[47]  J. Jukema,et al.  The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients , 2014, Heart.

[48]  J. Carrero,et al.  Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. , 2014, JAMA.

[49]  S. Fukuhara,et al.  Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS. , 2013, Kidney international.

[50]  Petr Neuzil,et al.  Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). , 2013, Journal of the American College of Cardiology.

[51]  C. Clase,et al.  Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[52]  Ron Pisters,et al.  Stroke and thromboembolism in atrial fibrillation. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[53]  C. Reutelingsperger,et al.  Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. , 2012, Blood reviews.

[54]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[55]  A. Capucci,et al.  Improving Stroke Risk Stratification Using the CHADS2 and CHA2DS2-VASc Risk Scores in Patients With Paroxysmal Atrial Fibrillation by Continuous Arrhythmia Burden Monitoring , 2011, Stroke.

[56]  P. Kerr,et al.  Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. , 2010, Kidney international.

[57]  A. Capucci,et al.  Presence and Duration of Atrial Fibrillation Detected by Continuous Monitoring: Crucial Implications for the Risk of Thromboembolic Events , 2009, Journal of cardiovascular electrophysiology.

[58]  B. Kestenbaum,et al.  Elevated risk of stroke among patients with end-stage renal disease. , 2003, Kidney international.

[59]  S. Hernández-Díaz,et al.  Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. , 2002, Journal of clinical epidemiology.

[60]  J. Lutz,et al.  Haemostasis in chronic kidney disease. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.